MARKET

ATNFW

ATNFW

180 Life Sciences Corp.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.820
-0.060
-3.19%
After Hours: 1.720 -0.1 -5.49% 18:08 04/16 EDT
OPEN
1.820
PREV CLOSE
1.880
HIGH
2.010
LOW
1.640
VOLUME
539.03K
TURNOVER
--
52 WEEK HIGH
2.970
52 WEEK LOW
0.0357
MARKET CAP
--
P/E (TTM)
-0.9242
1D
5D
1M
3M
1Y
5Y
BRIEF-180 Life Sciences Reports Closing Of $11.7 Mln Private Placement
reuters.com · 02/24 21:00
180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement
180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosi...
GlobeNewswire · 02/24 21:00
180 Life Sciences Corp. Announces $11.7 Million Private Placement
180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosi...
GlobeNewswire · 02/19 14:00
180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020
MENLO PARK, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that...
GlobeNewswire · 11/24/2020 15:00
180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs...
GlobeNewswire · 11/23/2020 13:30
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
MENLO PARK, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs...
GlobeNewswire · 11/17/2020 13:00
180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV
Company Now Publicly Traded on Nasdaq Under the ticker ATNFMENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused...
GlobeNewswire · 11/10/2020 16:46
4 SPAC Mergers: What The KBLM, ACAM, PANA And SMMC Deals Mean For Investors
Benzinga · 10/25/2020 18:24
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNFW. Analyze the recent business situations of 180 Life Sciences Corp. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
George Hornig
Chief Executive Officer/Director
Marlene Krauss
Chief Operating Officer/Director
Joseph Williamson
Director
Larry Gold
Independent Director
Sherrill Neff
Independent Director
Andrew Sherman
No Data
About ATNFW
180 Life Sciences Corp., (180 Life Sciences) formerly KBL Merger Corp. IV., is a research and development company. The Company is focused on research into solving one of the diseases is inflammation. The Company consists of three programs developing drugs in separate areas of inflammation. The Company’s pipeline, including Fibrosis and Anti-TNF, SCAs and a7nAChR. The Fibrosis and Anti-TNF treats diseases like Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), nonalcoholic steatohepatitis (NASH). The SCAs includes chronic pain and early arthritis. The a7nAChR includes smoking cessation induced ulcerative colitis.

Webull offers kinds of 180 Life Sciences Corp stock information, including NASDAQ:ATNFW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNFW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNFW stock methods without spending real money on the virtual paper trading platform.